Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 9
2014 25
2015 83
2016 242
2017 426
2018 504
2019 561
2020 66
Text availability
Article attribute
Article type
Publication date

Search Results

1,706 results
Results by year
Filters applied: . Clear all
Page 1
Treatment of Progressive Multifocal Leukoencephalopathy with Pembrolizumab.
Rauer S, Marks R, Urbach H, Warnatz K, Nath A, Holland S, Weiller C, Grimbacher B. Rauer S, et al. N Engl J Med. 2019 Apr 25;380(17):1676-1677. doi: 10.1056/NEJMc1817193. Epub 2019 Apr 10. N Engl J Med. 2019. PMID: 30969507 No abstract available.
Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy.
Cortese I, Muranski P, Enose-Akahata Y, Ha SK, Smith B, Monaco M, Ryschkewitsch C, Major EO, Ohayon J, Schindler MK, Beck E, Reoma LB, Jacobson S, Reich DS, Nath A. Cortese I, et al. N Engl J Med. 2019 Apr 25;380(17):1597-1605. doi: 10.1056/NEJMoa1815039. Epub 2019 Apr 10. N Engl J Med. 2019. PMID: 30969503 Clinical Trial.
Pembrolizumab for all PD-L1-positive NSCLC.
Smit EF, de Langen AJ. Smit EF, et al. Lancet. 2019 May 4;393(10183):1776-1778. doi: 10.1016/S0140-6736(18)32559-5. Epub 2019 Apr 4. Lancet. 2019. PMID: 30955976 No abstract available.
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Vandormael K, Riccio A, Yang J, Pietanza MC, Brahmer JR. Reck M, et al. J Clin Oncol. 2019 Mar 1;37(7):537-546. doi: 10.1200/JCO.18.00149. Epub 2019 Jan 8. J Clin Oncol. 2019. PMID: 30620668 Clinical Trial.
Pembrolizumab in lung cancer: current evidence and future perspectives.
Palumbo G, Carillio G, Manzo A, Montanino A, Sforza V, Costanzo R, Sandomenico C, Manna C, Luca G, Piccirillo MC, Daniele G, Cecio R, Botti G, Totaro G, Muto P, Picone C, Esposito G, Normanno N, Morabito A. Palumbo G, et al. Future Oncol. 2019 Oct;15(29):3327-3336. doi: 10.2217/fon-2019-0073. Epub 2019 Aug 21. Future Oncol. 2019. PMID: 31432705 Clinical Trial.
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators. Mok TSK, et al. Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4. Lancet. 2019. PMID: 30955977 Clinical Trial.
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.
Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, Manzuk L, Piha-Paul SA, Xu L, Zeigenfuss S, Pruitt SK, Leary A. Chung HC, et al. J Clin Oncol. 2019 Jun 10;37(17):1470-1478. doi: 10.1200/JCO.18.01265. Epub 2019 Apr 3. J Clin Oncol. 2019. PMID: 30943124 Clinical Trial.
Pembrolizumab for the treatment of diffuse large B-cell lymphoma.
Sheikh S, Kuruvilla J. Sheikh S, et al. Expert Opin Biol Ther. 2019 Nov;19(11):1119-1126. doi: 10.1080/14712598.2019.1659777. Epub 2019 Aug 28. Expert Opin Biol Ther. 2019. PMID: 31456438 Review.
1,706 results
Jump to page
Feedback